Bill Zartler, Solaris Energy Infrastructure Chairman and CEO, joins 'Power Lunch' to discuss rallying 400 percent in the last ...
Approval rests on the late-stage SOLARIS study, where investigators reported better overall symptoms, a clear drop in illness ...
The FDA has approved olanzapine extended-release injectable suspension (Weltruza; Teva Pharmaceuticals), a once-monthly ...
A number of stocks fell in the afternoon session after surging long-term Treasury yields reached multi-decade highs and energy market tightness prompted global emergency reserve actions. CNBC reported ...
The U.S. Food and Drug Administration (FDA) recently approved Teva Pharmaceutical Industries Ltd. TEVA to market Weltruza, a ...
APTA TRANSform & EXPO 2026 in Chicago brought new market entries and vehicle concepts in a context that showed a clear focus ...
Situated in a bustling premium hub, the Solaris Mont Kiara outlet is designed to elevate the neighbourhood's culinary scene.
WELTRUZA ™ (olanzapine) for extended-release injectable suspension is the first and only once-monthly subcutaneous long-acting injectable (LAI) ...
In an interview with CNBC, Solaris Energy Infrastructure’s CEO Bill Zartler said that higher interest rates do not seem to be ...
Teva stock is a "Hold" as its "Pivot to Growth" strategy shows early promise but requires further execution. Click for more ...
- Solaris Energy SEI-4.42% Infrastructure finances AI data center power plants via high-interest debt, leasing equipment to customers under long-term contracts. - Rising borrowing costs (6.375%-7%) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results